

A Cohort Study to Investigate Sex-specific Differences in ANCA-associated Glomerulonephritis Outcomes

Jennifer Scott

Trinity Health Kidney Centre, Trinity College Dublin

Carolina Canepa

UCL Department of Renal Medicine, Royal Free Hospital

Antonia Buettner

Trinity Health Kidney Centre, Trinity College Dublin

Louise Ryan

Trinity Health Kidney Centre, Trinity College Dublin

Brona Moloney

Trinity Health Kidney Centre, Trinity College Dublin

Sarah Cormican

Regenerative Medical Institute (REMEDI) at CÚRAM Centre for Research in Medical Devices, School, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway

Cathal Walsh

Department of Mathematics and Statistics, University of Limerick

Arthur White

Department of Statistics, Trinity College Dublin

Alan D Salama

UCL Department of Renal Medicine, Royal Free Hospital

Mark A. Little (✉ mlittle@tcd.ie)

Trinity Health Kidney Centre, Trinity College Dublin

Research Article

Keywords: ANCA associated vasculitis (AAV), Gender, Outcomes, End-stage-kidney-disease (ESKD)

Posted Date: April 12th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-401451/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Introduction

Data surrounding sex-specific differences in ANCA-associated vasculitis glomerulonephritis (ANCA-GN) outcomes is sparse. We hypothesised that the previously observed increased risk of end-stage kidney disease (ESKD) in males is driven by sex-specific variation in immunosuppression dosing.

Methods

Patients were recruited to the Irish Rare Kidney Disease Registry or followed by the Royal Free Hospital vasculitis team (2012-2020). Inclusion criteria: prior diagnosis of ANCA-GN (biopsy proven pauci-immune glomerulonephritis) and positive serology for anti-MPO or –PR3 antibodies. Renal and patient survival, stratified by sex and Berden histological class, was analysed. The cumulative- and starting dose/kilogram of induction agents and prednisolone, respectively, was compared between sexes.

Results

332 patients were included. Median follow-up was time 40.2 months (IQR 17.3–69.2). 73 (22%) reached ESKD and 47 (14.2%) died. Overall 1- and 5-year renal survival was 82.2% and 76.7% in males and 87.1% and 82.0% in females, respectively (p 0.13). The hazard ratio for ESKD in males versus females, after adjustment for age, ANCA serology, baseline creatinine and histological class was 1.07 (95% CI 0.59–1.93). There was no difference between sexes in the dose/kilogram of any induction agent.

Conclusion

We did not observe a strong impact of sex on renal outcome in ANCA-GN. Treatment intensity does not vary by sex.

Introduction

ANCA-associated vasculitis (AAV) is a rare multi-system autoimmune disease, which results in rapidly progressive glomerulonephritis and immune-mediated destruction of other organs. It is characterised by a necrotising pauci-immune small-vessel vasculitis, with a relapsing and remitting course. AAV comprises three main clinico-pathological syndromes: Microscopic polyangiitis (MPA), Granulomatosis with polyangiitis (GPA) and Eosinophilic granulomatosis with polyangiitis (EGPA). Despite treatment advances, AAV still carries a 2.7-fold increased risk of death compared with the general population¹ and a significant proportion of patients develop end-stage kidney disease (ESKD)²⁻⁴. The Berden histological classification system splits patients into four groups according to the predominant histological pattern: focal (\geq 50% normal glomeruli), crescentic (\geq 50% cellular crescents), sclerotic (\geq 50% globally sclerotic glomeruli) and mixed (all others). Multiple studies demonstrate that this classification system is predictive of ESKD risk⁵⁻¹⁰.

Unlike most autoimmune diseases, AAV displays a slight male predominance^{11,12}, with the male: female ratio reported as 1.0:0.9¹³. Proteinase 3 (PR3)-ANCA is more prevalent than myeloperoxidase (MPO)-ANCA in males¹⁴. However, few data exist about sex-specific differences in AAV glomerulonephritis (ANCA-GN) outcomes. A recent study¹⁴ demonstrated that males have a significantly higher risk of progression to ESKD, particularly in those with crescentic Berden class. A limitation of this study was the lack of personalised treatment data to allow modelling for association with renal outcomes.

We sought to validate the findings of Bjørneklett et al¹⁴ using a multi-national cohort, specifically, that the risk of developing ESKD is lower in females, across all histological classes of AAV. We also hypothesised that this difference would be based on a higher effective immunosuppression dose in women, due to lower lean body mass.

Methods

Study Participants

Participants of this retrospective cohort study were either previously recruited to the national Irish Rare Kidney Disease (RKD) Registry and Biobank¹⁵, or followed by the vasculitis team at the Royal Free Hospital (RFH), London (United Kingdom (U.K.)), between 2012-2020. Participants had to have a prior diagnosis of AAV pauci-immune glomerulonephritis, confirmed on kidney biopsy, with at least three glomeruli^{5,14}, and positive serology for anti-MPO or –PR3 antibodies. Patients with secondary vasculitis or dual anti-glomerular basement membrane disease were excluded, in accordance with the European Medicines Agency algorithm¹⁶. Ethical approval for the study was granted by the Tallaght University Hospital / St. James's Hospital Joint Research Ethics Committee (ref 2018-10 List 33 (7)). All RKD participants provided written informed consent. In the U.K., the Health Research Authority decision tool determined that additional ethical approval was not required for the RFH cohort, as the study was deemed service evaluation. Our research was performed in accordance with relevant guidelines and regulations.

Study Assessments

We collected data on age, sex, ethnicity, AAV phenotype, ANCA serotype, creatinine ($\mu\text{mol/L}$), weight (kg) and Berden score on renal biopsy. Treatment data was also collected, including cumulative induction cyclophosphamide and rituximab dose induction and the starting dose of prednisolone. To minimise the risk of incomplete induction treatment data, only cases with a realistic treatment schedule were included: >3 doses of IV cyclophosphamide or >1 rituximab dose in the first 6 months of treatment. The observation period was from the date of diagnosis to the occurrence of the first event (ESKD, death or 30th September 2020).

Statistical Analysis

The primary outcome was time to ESKD. ESKD was defined by commencement of renal replacement therapy (and continued for at least 90 days), including dialysis and renal transplantation. The secondary outcome was time to death. A composite of time to ESKD or death was also investigated. The cumulative dose per kilogram of each induction agent was calculated for a subgroup of participants for whom complete induction treatment data was available (n=189). The starting dose of prednisolone per kilogram was also obtained. Continuous variables are reported as mean (standard deviation, SD) or median (interquartile range, IQR, if not normally distributed), and compared using the independent sample t-test or Mann-Whitney U test, respectively. Categorical variables are summarised by frequency and percentage (%) and compared using the chi-square test. Renal survival was determined using Kaplan-Meier survival analysis. Analyses were censored for death or final visit. Between group comparisons were performed using the log-rank test. Renal and patient survival was stratified by sex and Berden histological class. Cox regression analysis was used to calculate the hazard ratio (HR) of ESKD in males versus females, with adjustment for age, ANCA serology, creatinine at diagnosis and Berden histological class. $P < 0.05$ was considered statistically significant. All statistical analyses were performed using RStudio (Version 1.2.5001). The following R packages were used: *dplyr*, *forcats*, *tableone*, *ggplot2*, *survival* and *survminer*.

Results

Participant Characteristics

332 patients met the inclusion criteria (Table 1), comprising 256 (77.1%) and 76 (22.9%) patients from the Irish and British cohorts, respectively. The mean age was 62 years (SD 15) and 194 (58.4%) were male, mainly Caucasian (92.2%). 217 (65.4%) were diagnosed with MPA, 92 (27.7%) GPA, 7 (2.1%) EGPA and 16 (4.8%) were unclassified AAV. 199 (60.1%) displayed MPO-ANCA positivity. Baseline creatinine was 278 $\mu\text{mol/L}$ (IQR 158 – 450). Median follow-up time was 40.2 months (IQR 17.3 – 69.2). During this time, 73 (22%) reached ESKD and 47 (14.2%) died.

Table 1 displays baseline characteristics stratified by sex. Females were older (mean age 65 years in females versus 61 years in males, p 0.009) with a trend towards more MPO-ANCA positivity compared to males (66.7% versus 55.4%, p 0.052). Males had slightly better renal function at baseline (eGFR 19 (10 – 38) ml/min/1.73m² in males versus 16 (9 – 34) ml/min/1.73m² in females), but this was not statistically significant. Females were lighter (female mean weight 69.3kg versus 82.5kg in males, p <0.001). There were no other significant differences in baseline characteristics between males and females.

Renal Survival

Overall, renal survival was 84% (95% confidence interval (CI) 80 – 88) at 1 year and 79% (95% CI 74 – 84) at 5 years. We observed an excess of ESKD in males in the first six months after diagnosis, but the probability of ESKD was not significantly higher in males over the full period of observation (Figure 1a). There was also no significant difference in renal survival between males and females when stratified by Berden histological class (Table 2 and Figures 1b-1e). The overall 1- and 5-year renal survival was 82.2% (95% CI 76.9 – 87.8) and 76.7% (95% CI 70.4 – 83.5) in males and 87.1% (95% CI 81.6 – 93.1) and 82.0% (95% CI 75.0 – 89.7) in females, respectively. The hazard ratio (HR) for ESKD in males versus females, after adjustment for age, ANCA serology, baseline creatinine and histological class was 1.07 (95% CI 0.59 – 1.93, p 0.82).

Patient and Renal Survival

There was no difference in the composite outcome of patient and renal survival between sexes (Figure 2), or when stratified by histological class (Table 3). Cox regression analysis showed that the HR for ESKD/death in males versus females, after adjustment for age, ANCA serology, baseline creatinine and histological class was 1.14 (95% CI 0.70 – 1.88, p 0.60).

Induction treatment stratified by sex

To test whether any observed effects of sex on survival may be influenced by standardised (non-weight based) dosing of immunosuppression, we analysed the weight adjusted doses delivered in those in whom complete data on individual induction immunosuppression was available (n =189). The median cumulative dose per kilogram for intravenous cyclophosphamide, oral cyclophosphamide and rituximab is shown Table 4. There was no significant difference between males and females for any agent.

Discussion

In our international, multi-centre study, we did not find a significant sex-specific difference in ANCA-GN outcomes. This contrasts with the increased risk of progression to ESKD for Norwegian males with ANCA-GN, reported by Bjørneklett et al¹⁴. Our findings were similar when combining ESKD and death as a composite outcome: there was no difference between males and females.

Norwegian males with ANCA-GN, reported by Bjørneklett et al¹⁴, were found to have a 2.44-fold increased risk of ESKD (HR 2.44, 95% CI 1.56 – 3.82, $p < 0.001$), after adjustment for age, ANCA serology, eGFR, and histological classification. This is consistent with prior observations in all-cause CKD where kidney function declines more rapidly and the risk of ESKD is higher in men^{17,18}. Data from the Norwegian study was collected between 1991-2012 when the standard of care was oral cyclophosphamide. This differs from our study which commenced in 2012, after the publication of the CYCLOPS trial¹⁹, after which intravenous cyclophosphamide gained popularity. It has been postulated that women are more adherent to daily oral medication regimes, which may play a role in the difference observed by Bjørneklett et al¹⁴, but not in the later pulsed intravenous regimes which predominate in our study. Importantly, like the previous study¹⁴, baseline kidney function in males was slightly better than in females, so this factor should not bias in favour of a better renal outcome in females, and baseline kidney function was included as a confounder in the multivariate model. Overall, our cohort had more advanced kidney disease at presentation: median baseline estimated Glomerular Filtration Rate (CKD-EPI, eGFR) 17.5 ml/min/1.73 m², versus 34 ml/min/1.73 m² in the Norwegian study. Despite this, and the higher proportion of MPO-ANCA positivity in our cohort (which in itself a risk factor for ESKD²⁰), a similar proportion of patients in both cohorts progressed to ESKD, in keeping with that observed in other recent work³. This observation probably reflects the improvement in overall AAV care over the last few decades³, which may have eliminated the sex-specific discrepancy in renal outcome seen prior to 2012.

In contrast to the literature^{14,21}, we identified that MPO-ANCA is more prevalent than PR3-ANCA in males. We also identified a higher proportion of MPO-ANCA positivity overall (60.1%) compared to the Norwegian study (46.0%), which is in keeping with the known latitudinal gradient of PR3:MPO ANCA specificity²¹. This highlights the heterogenous nature of AAV across different geographic regions, despite using identical inclusion criteria. This geographical diversity, potentially underpinned by genetics²², may account for inconsistencies in renal outcome across different cohorts.

We repeated the Kaplan-Meier analysis stratified for Berden histological class. In keeping with the original Berden description and the recent re-validation by van Daalen et al¹⁰, we demonstrated that the focal subclass carries the best renal prognosis, while the sclerotic class performs the worst. The crescentic and mixed classes displayed similar prognosis. We did not observe an interaction between histological class and gender on ESKD risk. Notably, the large sex-specific difference observed by Bjørneklett et al¹⁴ in patients with the crescentic subclass was not replicated in our cohort.

Our aim was to build on the findings of Bjørneklett et al¹⁴ by using the very granular treatment data available to us, to explore whether their findings were due to sex-dependent variation in cumulative immunosuppression dosing, relative to body mass. We hypothesised that females received a higher effective induction immunosuppression dose due to their lower average body mass when fixed dosing regimens are administered. However, we found no difference between sexes in the cumulative dose normalised to body weight of any of the induction agents. It is possible we were underpowered to detect a difference as complete treatment data was missing in 43% of the cohort, but our evidence suggests sex-dependent variation in treatment intensity is not a factor in determining renal outcome.

To our knowledge, our study is the second of its kind to investigate sex-specific differences in renal outcomes in patients with AAV glomerulonephritis. Our large international multi-centre cohort study benefits from detailed longitudinal data including comprehensive individual treatment records. However, due to the observational nature of our data, there is a possibility that treatment data is incomplete, resulting in inaccurate conclusions. It also remains possible that our study is under-powered to detect small effects, although, if present, these would be unlikely to be clinically significant. To mitigate this we restricted this sub-analysis to include patients with a realistic cumulative dose (>3 doses of IV cyclophosphamide or >1 rituximab dose in the first 6 months of treatment). Study endpoints were obtained retrospectively from hospital records. Therefore, there is a possibility that death records are incomplete if the event occurred outside of the hospital. However, given that AAV patients are generally followed up in hospital settings, this is unlikely. In addition, sustained chronic kidney disease stage 5 is increasingly recognised as part of the ESKD definition, but was not included in our study (in line with the Norwegian study). We chose to use identical inclusion criteria and definitions to Bjørneklett et al¹⁴ to enable accurate validation. Similarly, only biopsy proven cases were included, which results in selection bias towards more severe cases. It is possible that a significant difference in renal outcome exists between sexes when all patients with renal involvement are included.

In summary, we did not identify any clear sex-specific difference in renal outcome when stratified by Berden histological class. Furthermore, we found no evidence to support that any difference is due to sex-dependent variation in cumulative immunosuppression dosing. On the contrary, we found that weight-based dosing regimens are now standard practice in Ireland, and treatment intensity does not vary by sex. There is a potential to further explore gender differences in well characterized registries with granular longitudinal follow-up, and to utilize the expanding interoperable nature of our European registries through initiatives such as FAIRVASC²³. When designing future multi-centre collaborative studies, we should consider the biopsychosocial influences of sex variance in AAV, in the context of outcomes and treatment- response and toxicity.

Declarations

Competing Interests

The authors declare no competing interests.

Funding

Dr Jennifer Scott is a Wellcome-HRB Irish Clinical Academic Training (ICAT) Fellow, and this work was performed within the Irish Clinical Academic Training (ICAT) Programme, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland. MAL received funding from Health Research Board / Irish Nephrology Society (MRCG-2016-12) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 813545.

Acknowledgements

The authors would like to thank all participants who are enrolled in the Irish Rare Kidney Disease and Biobank and patients who attend the vasculitis centre at the Royal Free Hospital, London, without whom this research would not be possible. We would also like to thank all nephrologists and pathologists in Ireland and London who were integral to

the quality of the data collected. We also acknowledge the dedication of the Tallaght University Hospital / St. James's Hospital Joint Research Ethics Committee, who reviewed and approved our study.

Author contributions

JS, CW, AW, AS and ML designed the study. JS performed the data analysis, under the guidance of CW, AW and ML. JS and ML drafted the initial version of the article. All authors contributed to reviewing and revising all drafts of the article. CC, AB, LR, BM and SC were critical to data collection, cleaning and initial centre-based analysis. ML approved the final version of the manuscript for submission.

Data Availability Statement

The complete raw data underlying this article cannot be shared publicly due to the potentially identifiable nature of the data, due to the rarity of ANCA-associated vasculitis and the fact that the follow-up centres are published in this paper. Anonymised data will be shared on reasonable request to the corresponding author.

References

1. Tan, J. A. *et al.* Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies. *Ann Rheum Dis.* **76**, 1566–1574 <https://doi.org/10.1136/annrheumdis-2016-210942> (2017).
2. Moiseev, S., Novikov, P., Jayne, D. & Mukhin, N. End-stage renal disease in ANCA-associated vasculitis. *Nephrology Dialysis Transplantation.* **32**, 248–253 <https://doi.org/10.1093/ndt/gfw046> (2017).
3. Trejo, M. A. C. W. *et al.* Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: Unpredictable, but predictive of renal outcome. *Rheumatology (United Kingdom).* **58**, 103–109 <https://doi.org/10.1093/rheumatology/key260> (2019).
4. Rhee, R. L. *et al.* Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis With Renal Disease. *Arthritis and Rheumatology.* **68**, 1711–1720 <https://doi.org/10.1002/art.39614> (2016).
5. Bjørneklett, R., Sriskandarajah, S. & Bostad, L. Prognostic Value of Histologic Classification of ANCA-Associated Glomerulonephritis. *Clinical journal of the American Society of Nephrology: CJASN.* **11**, 2159–2167 <https://doi.org/10.2215/CJN.04800516> (2016).
6. Hilhorst, M. *et al.* Estimating renal survival using the ANCA-associated GN classification. *J Am Soc Nephrol.* **24**, 1371–1375 <https://doi.org/10.1681/ASN.2012090912> (2013).
7. Berden, A. E. *et al.* Histopathologic Classification of ANCA-Associated Glomerulonephritis. *Journal of the American Society of Nephrology.* **21**, 1628–1636 <https://doi.org/10.1681/asn.2010050477> (2010).
8. Chang, D. *et al.* Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. *Nephrology Dialysis Transplantation.* **27**, 2343–2349 <https://doi.org/10.1093/ndt/gfr643> (2011).
9. Tanna, A. *et al.* Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. *Nephrology Dialysis Transplantation.* **30**, 1185–1192 <https://doi.org/10.1093/ndt/gfu237> (2014).
10. van Daalen, E. E. *et al.* Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis. *Clinical journal of the American Society of Nephrology: CJASN.* **15**, 1103–1111

<https://doi.org/10.2215/CJN.14561119> (2020).

11. Watts, R. A. *et al.* Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. *Nephrology Dialysis Transplantation*. **30**, i14–i22 <https://doi.org/10.1093/ndt/gfv022> (2015).
12. Jennette, J. C. & Nachman, P. H. ANCA Glomerulonephritis and Vasculitis. *Clinical Journal of the American Society of Nephrology: CJASN*. **12**, 1680–1691 <https://doi.org/10.2215/cjn.02500317> (2017).
13. Jennette, J. C. Rapidly progressive crescentic glomerulonephritis. *Kidney Int*. **63**, 1164–1177 <https://doi.org/10.1046/j.1523-1755.2003.00843.x> (2003).
14. Bjørneklett, R., Solbakken, V., Bostad, L. & Fismen, A. S. Exploring sex-specific differences in the presentation and outcomes of ANCA-associated vasculitis: a nationwide registry-based cohort study. *International Urology and Nephrology*. **50**, 1311–1318 <https://doi.org/10.1007/s11255-018-1888-8> (2018).
15. <https://www.tcd.ie/medicine/thkc/research/rare.php>, (
16. Watts, R. *et al.* Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Annals of the rheumatic diseases*. **66**, 222–227 <https://doi.org/10.1136/ard.2006.054593> (2007).
17. Carrero, J. J., Hecking, M., Chesnaye, N. C. & Jager, K. J. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. *Nature Reviews Nephrology*. **14**, 151–164 <https://doi.org/10.1038/nrneph.2017.181> (2018).
18. Minutolo, R. *et al.* Sex Differences in the Progression of CKD Among Older Patients: Pooled Analysis of 4 Cohort Studies. *American Journal of Kidney Diseases*. **75**, 30–38 <https://doi.org/10.1053/j.ajkd.2019.05.019> (2020).
19. de Groot, K. Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. *Annals of Internal Medicine*. **150**, 670 <https://doi.org/10.7326/0003-4819-150-10-200905190-00004> (2009).
20. Flossmann, O. *et al.* Long-term patient survival in ANCA-associated vasculitis. *Ann Rheum Dis*. **70**, 488–494 <https://doi.org/10.1136/ard.2010.137778> (2011).
21. Weiner, M. *et al.* Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. *Nephrology Dialysis Transplantation*. **34**, 301–308 (2019).
22. Watts, R. A., MacGregor, A. J. & Mackie, S. L. HLA allele variation as a potential explanation for the geographical distribution of granulomatosis with polyangiitis. *Rheumatology*. **54**, 359–362 <https://doi.org/10.1093/rheumatology/keu321> (2014).
23. <https://fairvasc.eu/the-project/>, (

Tables

Table 1: Baseline characteristics in the total cohort and stratified by sex

	All	Female	Male	<i>p</i>
<i>N</i> *	332	138 (41.6)	194 (58.4)	
Origin = RKD /RFH*	256/76 (77.1/22.9)	99/39 (71.7/28.3)	157/37 (80.9/19.1)	0.067
Age at diagnosis**	62.5 (14.7)	65.0 (14.8)	60.7 (14.4)	0.009
Ethnicity*				0.729
White	306 (92.2)	125 (90.6)	181 (93.3)	
Asian	12 (3.6)	6 (4.3)	6 (3.1)	
Black	6 (1.8)	4 (2.9)	2 (1.0)	
Mixed	3 (0.9)	1 (0.7)	2 (1.0)	
Other	5 (1.5)	2 (1.4)	3 (1.5)	
AAV phenotype*				0.18
MPA	217 (65.4)	96 (69.6)	121 (62.4)	
GPA	92 (27.7)	31 (22.5)	61 (31.4)	
EGPA	7 (2.1)	2 (1.4)	5 (2.6)	
ANCA vasculitis unclassified	16 (4.8)	9 (6.5)	7 (3.6)	
MPO-ANCA specificity*	199 (60.1)	92 (66.7)	107 (55.4)	0.052
Baseline creatinine (µmol/L)***	278 [158.0, 450.0]	263 [140.5, 412.0]	288 [165.5, 504.5]	0.065
Baseline eGFR (ml/min/1.73m ²)***		16 [9, 34]	19 [10, 38]	
Weight (kg)**	77.1 (22.9)	69.3 (16.2)	82.5 (25.2)	<0.001
Berden histological class*				0.415
Crescentic	97 (31.7)	42 (33.1)	55 (30.7)	
Focal	90 (29.4)	37 (29.1)	53 (29.6)	
Mixed	79 (25.8)	36 (28.3)	43 (24.0)	
Sclerotic	40 (13.1)	12 (9.4)	28 (15.6)	
Follow up (months)***	40.2 [17.3, 69.2]	36.0 [15.5, 57.8]	41.5 [19.4, 75.7]	0.091
End-stage kidney disease*	73 (22.0)	24 (17.4)	49 (25.3)	0.116
Death*	47 (14.2)	21 (15.2)	26 (13.4)	0.758

*Frequency (%), **Mean (standard deviation), ***Median (inter-quartile range)

Rare Kidney Disease Registry (RKD), Ireland. Royal Free Hospital (RFH), London, U.K. Microscopic polyangiitis (MPA), Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with polyangiitis (EGPA), Estimated Glomerular Filtration Rate (CKD-EPI, eGFR) was calculated from baseline creatinine.

Missing data: baseline creatinine for females (n=20), males (n=27), weight for females (n=20), males (n=23).

Table 2: Renal survival at 1- and 5-years follow-up, stratified by gender and Berden classification

Characteristic	N		ESKD		1-year		5-year		p value
	Males	Females	Males	Females	Males (% (%, 95% CI)	Females (% (%, 95% CI)	Males (% (%, 95% CI)	Females (% (%, 95% CI)	
All	194	138	49	24	82.2 (76.9 – 87.8)	87.1 (81.6 – 93.1)	76.7 (70.4 – 83.5)	82.0 (75.0 – 89.7)	0.13
Focal	53	37	2	2	100 (1.0 – 1.0)	96.9 (91.0 – 1.0)	97.4 (92.4 – 1.0)	96.9 (91.0 – 1.0)	0.73
Mixed	43	36	11	7	81.4 (70.6 – 93.9)	87.9 (77.5 – 99.8)	75.9 (63.8 – 90.2)	82.8 (69.6 – 98.5)	0.25
Crescentic	55	42	13	7	87.2 (78.7 – 96.5)	83.1 (72.4 – 95.4)	76.4 (64.7 – 90.3)	83.1 (72.4 – 95.4)	0.52
Sclerotic	28	12	17	7	44.4 (28.4 – 68.0)	64.8 (42.1 – 99.8)	44.4 (28.4 – 68.0)	32.4 (13.1 – 80.4)	0.78
Missing*	15	11							

*Berden histological class missing in n=26.

Table 3: Patient and renal survival at 1- and 5-years follow-up, stratified by gender and Berden classification

Characteristic	N		ESKD/death		1-year		5-year		p value
	Males	Females	Males	Females	Males (% (%, 95% CI)	Females (% (%, 95% CI)	Males (% (%, 95% CI)	Females (% (%, 95% CI)	
All	194	138	60	40	80.6 (75.2 – 86.4)	81.8 (75.4 – 88.7)	71.3 (64.5 – 78.8)	69.4 (60.6 – 79.4)	0.79
Focal	53	37	7	5	98.1 (94.4 – 100)	88.3 (78.1 – 99.8)	87.4 (77.4 – 98.6)	88.3 (78.1 – 99.8)	0.83
Mixed	43	36	12	13	81.4 (70.6 – 93.9)	85.0 (73.7 – 98.1)	69.5 (54.5 – 88.7)	66.6 (50.1 – 88.6)	0.96
Crescentic	55	42	16	12	85.3 (76.3 – 95.2)	75.7 (63.6 – 90.0)	74.8 (63.0 – 88.8)	72.8 (60.2 – 88.0)	0.93
Sclerotic	28	12	19	8	40.8 (25.8 – 64.7)	64.8 (42.1 – 99.8)	35.7 (21.1 – 60.6)	16.2 (3.1 – 85.0)	0.79
Missing*	15	11							

*Berdens histological class missing in n=26.


Table 4: Induction immunosuppression dose per kilogram, stratified by gender

Drug (mg)	N		Median (IQR) (mg/kg)		p value
	Female	Male	Female	Male	
Cumulative IV Cyclophosphamide dose/kg	81	58.15 (53.38, 73.89)	64.23 (51.52, 79.48)	0.45	
Cumulative PO Cyclophosphamide dose/kg	49	86.70 (68.15, 146.92)	126.11 (74.07, 201.53)	0.35	
Cumulative Rituximab dose/kg	59	30.77 (23.53, 38.46)	28.85 (21.17, 32.60)	0.11	
Starting Prednisolone dose/kg	200	0.77 (0.64, 0.76)	0.71 (0.57, 0.70)	0.05	


Milligram (mg), kilogram (kg), intravenous (IV), oral (PO)

Figures


a). Entire cohort




b). Focal histology



c). Mixed histology



d). Crescentic histology



e). Sclerotic histology




Figure 1

Kaplan-Meier plots demonstrating renal survival in males versus females in a). the entire cohort, and in those with b). focal histology, c). mixed histology, d). crescentic histology and e). sclerotic histology.




Figure 2

Kaplan-Meier plot demonstrating patient and renal survival in males versus females.